Related Experiment Videos
[Benefits of intensive reduction of low density lipoprotein cholesterol]
1Departamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, INCICH, Juan Badiano No. 1, Col. Sección XVI, Tlalpan, 14080 México, D.F. cposadasr@yahoo.com
Insights
Lowering low-density lipoprotein cholesterol (LDL-C) with statins significantly reduces cardiovascular events in high-risk patients. Ongoing trials will further clarify optimal LDL-C reduction targets for atherosclerosis management.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Context:
- Elevated cholesterol is a primary driver of atherosclerosis.
- Statins (HMG CoA reductase inhibitors) are widely used for cholesterol reduction.
- Clinical trials confirm statin efficacy in reducing coronary events.
Purpose:
- To review current data on cholesterol reduction and cardiovascular events.
- To address the uncertainty regarding optimal low-density lipoprotein cholesterol (LDL-C) targets.
- To inform clinical practice while awaiting results from ongoing trials.
Summary:
- Epidemiological and intervention studies suggest a dose-response relationship between LDL-C lowering and cardiovascular event reduction.
- Lower LDL-C levels achieved through statin therapy correlate with better outcomes in high-risk individuals.
- The optimal extent of LDL-C reduction remains an active area of research.
Impact:
- Provides evidence supporting aggressive LDL-C lowering in high-risk patients.
- Highlights the ongoing need for research to define precise cholesterol treatment goals.
- Informs clinical decision-making regarding statin therapy for atherosclerosis prevention.
Abstract:
The role of elevated cholesterol in the initiation and progression of atherosclerosis is universally recognized. In the last 14 years, the inhibitors of the 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase (statins) have become one of the most widely used therapeutic agents to lower cholesterol levels. Individual large clinical trials, as well as a meta-analysis of five of these studies, have clearly demonstrated the effect of statin-induced low-density lipoprotein cholesterol (LDL-C) lowering in significantly reducing the risk of coronary events in patients with a history of coronary artery disease (CAD). However, there are a few remaining questions, and the most important uncertainty is to what extent should cholesterol be reduced? The results of three large ongoing trials, specifically designed to answer this question, will be available in about two years. In the meantime, this paper presents a short review of the data derived from epidemiological studies and large intervention trials, suggesting that, in patients at high risk, the lower the LDL-C induced by treatment, the better the chance of reducing the incidence of cardiovascular events.